Canine Nasal Carcinoma
Eligibility Requirements
• click on link below for details
Study Objective
Examine the efficacy of toceranib phosphate (Palladia) as a primary and/or adjuvant agent in the treatment of canine nasal carcinoma. Canine nasal carcinomas are common, locally aggressive tumors. Untreated patients survive an average of 3-5 months. Radiation therapy is currently the treatment of choice as it extends median survival times to 8-25 months, with a maximum tumor response approximately 3 months after completion of treatment. Long-term control of this tumor is rarely achieved, so new approaches to this uniformly fatal tumor are needed. All tumors must develop new blood vessels in order to grow. Palladia is a tyrosine kinase inhibitor that inhibits the development of new blood vessels by targeting receptors called vascular endothelial growth factor receptors. These receptors have been documented to occur in canine nasal tumors and early reports indicate that Palladia has primary activity in these tumors. Palladia has also been shown to sensitize tumor tissues to the effects of radiation therapy. Because of these findings, clinical investigation of Palladia as therapy for nasal carcinomas, alone or in combination with radiation therapy is needed to know if we can increase our efficacy in controlling these tumors in comparison to radiation therapy alone. We also need to monitor for any side effects.
Compensation
Your dog will receive free drug and monitoring tests (as outlined above) for adverse effects, as well as a follow-up CT scan at 90 days post-treatment (overall cost savings of approximately $3300). We expect treatment with Palladia will benefit dogs with nasal carcinoma by increasing response rates and prolonging disease free-intervals and overall survival times. Please click on the link for more details.
Location of Trial
Auburn, AL
More information
Examining the Efficacy of Toceranib Phosphate (Palladia®) as a Primary and/or Adjuvant Agent in the Treatment of Canine Nasal Carcinoma
Eligibility Requirements
• Histologically confirmed canine nasal carcinoma
• Pre-treatment CT scan confirming that the tumor does not extend through the cribiform plate into the brain parenchyma
• Greater than 24 months of age
• Greater than 3.1 kg body weight
• Estimated life expectancy greater than 6 weeks
• Adequate organ function
Study Objective
To identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of canine nasal carcinoma.
Compensation
The cost of the pre-treatment and post-treatment CT scan are fully funded The cost of Palladia is fully funded All patients will be staged with thoracic radiographs, baseline laboratory work, CT scan and submandibular lymph node aspirates (where possible). This cost would be the responsibility of the owner. All routine examination, bloodwork and medications for possible side effects/adverse events would be the responsibility of the pet owner. Please click on the link for more details.
Location of Trial
Tinton Falls, NJ
Columbus, OH
University of Georgia (Athens, Georgia)
More information
Activity of toceranib phosphate (Palladia™ ) alone or as a radiation sensitizing agent in the treatment of canine nasal carcinoma.
Eligibility Requirements
• Dogs with a diagnosis of nasal carcinoma, that are greater than 24 months of age, greater than 6.8 pounds of body weight, have greater than a 6 week estimated life expectancy, and have adequate organ function. They may not have evidence of extension of tumor into the brain, lymph node or any other metastasis, another known serious disorder incompatible with the study, or be pregnant or lactating. ty criteria goes here - hit enter to add more
Study Objective
The goal of this study is to determine the activity of toceranib phosphate (Palladia™ ) alone or as a radiation sensitizing agent in the treatment of canine nasal carcinoma. These findings will be compared to historical controls treated with radiation alone.
Compensation
Free drug and this drug has a value of $300 -$500 per month, free CT exams for monitoring of tumor, free follow up exams and lab tests (value $1500-$2000). Please click on the link for more details.
Location of Trial
Pullman, WA
More information
Tomotherapy clinical trials for dogs with nasal tumors: Conformal avoidance of eyes and brain
Eligibility Requirements
• Dogs with confirmed nasal tumors
Study Objective
To evaluate molecular imaging of the tumor to guide and individualize each dog’s treatment plan with the goal of prolonging overall survival.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Madison, WI
More information
| 
